|
| Title | Country | Date | Status | Phase | Conditions | Intervention | Age of patients | Estimated enrollment | Results |
|
| Treatment of Knee Osteoarthritis with Autologous Mesenchymal Stem Cells | Spain | 2010 to 2014 | Completed with results | 1 and 2 | Osteoarthritis, knee; knee
degenerative
disease; knee
Osteoarthritis | Autologous bone marrow mesenchymal stem cells (MSV) by articular injection | 18–76 | 12 | MSC therapy may be a valid alternative treatment for chronic knee osteoarthritis. The intervention is simple, does not require hospitalization or surgery, provides pain relief, and significantly improves cartilage quality. Orozco et al., 2013 [56]; Orozco et al., 2014 [55] |
| Treatment of Knee Osteoarthritis with Allogenic Mesenchymal Stem Cells | Spain | 2012 to 2014 | Completed with results | 1 and 2 | Osteoarthritis, knee; arthritis of knee; knee
osteoarthritis | Allogenic mesenchymal stromal cells injection (compared to hyaluronic acid injection) | 18–75 | 30 |
| Study to Compare the Efficacy and Safety of Cartistem and Microfracture in Patients with Knee Articular Cartilage Injury or Defect | Korea | 2009 to 2011 | Completed | 3 | Cartilage injury; osteoarthritis | Cartistem (allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo, combined with sodium hyaluronate)
(compared to microfracture treatment) | 18 and older | 104 | |
| Transplantation of Bone Marrow-Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis | Iran | 2009 to 2011 | Completed | 2 and 3 | Rheumatoid
arthritis | Bone marrow mesenchymal cell transplantation; (compared to placebo) | 18–65 | 60 | |
| Articular Cartilage Resurfacing With Mesenchymal Stem Cells In Osteoarthritis Of Knee Joint | Iran | 2009 to 2010 | Completed | 2 | Osteoarthritis | Mesenchymal stem cells injection | 18–65 | 6 | |
| The Effects of Intra-articular Injection of Mesenchymal Stem Cells in Knee Joint Osteoarthritis | Iran | 2010 to 2012 | Completed | 2 | Osteoarthritis | Bone marrow mesenchymal stem cell (compared to placebo) | 18–65 | 40 | |
| Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis | Spain | 2010 to 2013 | Completed | 1 and 2 | Osteoarthritis, knee; knee
Injuries; joint
diseases; rheumatic
diseases; cartilage diseases | Autologous mesenchymal stem cells (MSCs) knee implantation after “ex vivo” expansion | 18–65 | 15 | |
| Autologous Transplantation of Mesenchymal Stem Cells (MSCs) and Scaffold in Full-thickness Articular Cartilage | Iran | 2008 to 2010 | Completed | 1 | knee
osteoarthritis | Bone marrow-derived mesenchymal stem cells mixed with collagen I scaffold | 45–60 | 6 | |
| Side Effects of Autologous Mesenchymal Stem Cell Transplantation in Ankle Joint Osteoarthritis | Iran | 2010 to 2011 | Completed | 1 | Osteoarthritis | Bone marrow-derived mesenchymal stem cell | 18–65 | 6 | |
| Mesenchymal Stem Cell Transplantation in Osteoarthritis of Hip Joint | Iran | 2010 to 2011 | Completed | 1 | Hip osteoarthritis | Bone marrow mesenchymal stem cell injection | 18–65 | 6 | |
| “One-step” Bone Marrow Mononuclear Cell Transplantation in Talar Osteochondral Lesions | Italy | 2013 to 2016 | Recruiting | 3 | Osteochondritis | Bone marrow-derived cells transplantation on collagen scaffold | 15–50 | 140 | |
| Mesenchymal Stem Cells in Knee Cartilage Injuries | Jordan | 2014 to 2015 | Recruiting | 2 | Articular cartilage disorder of knee; osteoarthritis, knee | Autologous
mesenchymal
stem
cells | 40–68 | 16 | |
| Evaluation of Safety and Exploratory Efficacy of CARTISTEM, a Cell Therapy Product for Articular Cartilage Defects | USA and Korea | 2012 to 2015 | Recruiting | 1, 2 and 3 | Osteoarthritis, degenerative, degenerative injury, traumatic injury, knee | Cartistem (allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo, combined with sodium hyaluronate) | 18 and older | 12 | |
| Autologous Bone Marrow Mesenchymal Stem Cells Transplantation for Articular Cartilage Defects Repair | Brazil | 2012 to 2014 | Recruiting | 1 and 2 | Osteoarthritis | Bone marrow-derived mesenchymal stem cells | 25–65 | 10 | |
| Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA | Canada | 2015 to 2021 | Recruiting | 1 and 2 | Osteoarthritis of knee | Mesenchymal stem cells | 40–65 | 12 | |
| Mesenchymal Stem Cells Enhanced With PRP Versus PRP In OA Knee | India | 2013 to 2014 | Recruiting | 1 and 2 | Osteoarthritis, knee | Mesenchymal
stem cell
suspension | 40–75 | 24 | |
| Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma | Spain | 2014 to 2017 | Recruiting | 1 and 2 | Knee
osteoarthritis | Bone marrow mesenchymal stem cells (compared to Platelet Rich plasma (PRGF)) | 40–80 | 38 | |
| Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease | Sweden | 2014 to 2017 | Recruiting | 1 and 2 | Graft -versus-host-disease | Mesenchymal
stromal cells | 18–80 | 12 | |
| Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis | USA | 2013 to 2014 | Recruiting | 1 | Bilateral primary
osteoarthritis of knee | Autologous
bone marrow
aspirate | 18 and older | 25 | |
| Bone Marrow Stromal Cells for Inflammatory Bowel Diseases | USA | 2013 to 2019 | Recruiting | 1 | Inflammatory
bowel disease | Bone marrow
stromal cell
(BMSC)
infusion | 18–65 | 100 | |
| Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects | USA | 2014 to 2019 | Recruiting | | Degenerative lesion of articular cartilage of knee | adipose derived stem cells (compared to microfracture) | 18–40 | 40 | |
| Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Osteoarthritis | India | 2010 to 2012 | Enrolling by invitation | 1 and 2 | Osteoarthritis | Autologous
bone marrow stem cells | 30–70 | 10 | |
| Effectiveness and Safety of Autologous ADRC for Treatment of Degenerative Damage of Knee Articular Cartilage | Russian | 2015 | Enrolling by invitation | 1 and 2 | Osteoarthritis | Autologous
bone marrow stem cells | 20–85 | 12 | |
| Follow-Up Study of CARTISTEM Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect | Korea | 2012 to 2015 | Active, not recruiting | 3 | Degenerative
osteoarthritis;
defect of articular
cartilage | Cartistem (allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo, combined with sodium hyaluronate)
(compared to microfracture procedure) | 18 and older | 103 | |
| IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee. | Netherland | 2013 to 2015 | Active, not recruiting | 1 and 2 | Foreign-body reaction; inflammation; effusion (L) knee; knee pain swelling | Mesenchymal stromal cells mixed with fibrin cell carrier | 18–45 | 35 | |
| Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells | Spain | 2012 to 2015 | Active, not recruiting | 1 and 2 | Osteoarthritis | Bone marrow mesenchymal stem cells | 50–80 | 30 | |
| Autologous Adipose Stem Cells and Platelet Rich Plasma Therapy for Patients With Knee Osteoarthritis | Vietnam | 2013 to 2015 | Active, not recruiting | 1 and 2 | Knee
osteoarthritis | Autologous adipose tissue stromal vascular fraction and platelet rich plasma | 18 and older | 32 | |
| Mesenchymal Stem Cells in a Clinical Trial to Heal Articular Cartilage Defects | Norway | 2009 to 2018 | Active, not recruiting | 1 | Defect of articular cartilage | Mesenchymal stem cells or chondrocytes under a commercial available membrane | 18–50 | 50 | |
| Human Umbilical Cord Mesenchymal Stem Cell Transplantation in Articular Cartilage Defect | China |
2014 to 2016 | Not yet recruiting | 1 | Cartilage diseases; osteoarthritis | Human umbilical cord mesenchymal stem cells | 18–75 | 20 | |
| Clinical Trial of Stem Cell Based Tissue Engineered Laryngeal Implants | United Kingdom | 2015 to 2018 | Not yet recruiting | 1 and 2 | Disorder of upper respiratory system; laryngostenosis; tracheal stenosis | Stem cell based tissue engineered partial laryngeal implants (autologous-derived cells and decellularized human donor scaffolds) | 18 and older | 10 | |
| The Use of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Articular Cartilage Defects | Egypt | 2006 to 2014 | Unknown | 2 and 3 | Degenerative
arthritis; chondral defects; osteochondral
defects | Bone marrow mesenchymal stem cell implantation (after culture expansion in pellet) | 15–55 | 25 | |
| Intra-Articular Autologous Bone Marrow Mesenchymal Stem Cells Transplantation to Treat Mild to Moderate Osteoarthritis | Malaysia | 2011 to 2014 | Unknown | 2 | Osteoarthritis | Autologous bone marrow-derived mesenchymal stem cells (compared to Hyaluronic Acid) | 18–70 | 50 | |
| Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis | China | 2013 to 2014 | Unknown | 1 and 2 | Rheumatoid arthritis | Umbilical cord-derived mesenchymal stem cells (UC-MSCs)/rheumatoid arthritis with disease-modifying drugs (DMARDs)/: UC-MSC + DMARDS | 18–70 | 200 | |
| Autologous Mesenchymal Stem Cells versus Chondrocytes for the Repair of Chondral Knee Defects | Spain | 2011 to 2012 | Unknown | 1 and 2 | Articular cartilage lesion of the femoral condyle | Mesenchymal stem cells derived from adipose tissue | 18–55 | 30 | |
| Transplantation of Bone Marrow Stem Cells Stimulated by Proteins Scaffold to Heal Defects Articular Cartilage of the Knee | France | 2010 to 2014 | Unknown | 0 | Osteoarthritis; knee
osteoarthritis; osteochondritis
dissecans; osteonecrosis | Transplantation of nonculture expanded autologous bone marrow stem cells stimulated with a protein matrix and mixed in a collagen hydroxyapatite scaffold | 30–75 | 50 | |
| Peripheral Blood-derived Stem Cell Trial on Damaged Knee Cartilage | Malaysia | 2009 to 2012 | Unknown | | Damaged articular cartilage | Peripheral blood-derived stem cell and hyaluronic acid | 18–50 | 50 | |
|
